Loading clinical trials...
Loading clinical trials...
A Phase II Trial of Prostaglandin E2 Inhibition, Using Meloxicam, Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Conditions
Interventions
Meloxicam
Filgrastim
Locations
1
United States
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
Start Date
March 11, 2014
Primary Completion Date
November 6, 2018
Completion Date
February 21, 2019
Last Updated
February 21, 2021
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Sherif S. Farag
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions